Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of V0337 SO 01A suspension in gastro-oesophageal reflux disease (GORD)
2008-002562-60Phase 3Active
- Sponsor
- Pierre Fabre Laboratories
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastroesophageal reflux disease (GERD) comparing V0337 SO 01A suspension with Placebo (2 arms). Primary endpoint: Change in heartburn intensity. Started Nov 2008; status: active.
02
Drugs
sodium alginate + potassium bicarbonate
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2008-002562-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002562-60.